A federal appeals court in Philadelphia, as expected, has decided to consider and rule on AstraZeneca’s 340B contract pharmacy lawsuit in tandem with Sanofi and Novo Nordisk’s 340B contract pharmacy cases.
The U.S. Third Circuit Court of Appeals announced the move on April 28. Sanofi and Novo Nordisk’s cases were consolidated and decided together at the federal district court level.
A federal appeals court in Philadelphia, as expected, has decided to consider and rule on AstraZeneca’s 340B contract pharmacy lawsuit in tandem with Sanofi and Novo Nordisk’s 340B contract pharmacy cases.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
